Hidenori Yanagi

Dr. Hidenori Yanagi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
TNTakayoshi Nakajima
Takayoshi Nakajima
SIShinichi Ikuta
Shinichi Ikuta
MFMasataka Fujikawa
Masataka Fujikawa
LILisa Ikuta
Lisa Ikuta
GMGoshi Matsuki
Goshi Matsuki
NYNaoki Yamanaka
Naoki Yamanaka

21 October 2024 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
TNTakayoshi Nakajima
Takayoshi Nakajima
SIShinichi Ikuta
Shinichi Ikuta
TATsukasa Aihara
Tsukasa Aihara
LILisa Ikuta
Lisa Ikuta
GMGoshi Matsuki
Goshi Matsuki
NYNaoki Yamanaka
Naoki Yamanaka

15 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Hiroshi DoiHiroshi Doi
Hiroshi Doi
HYHiroyuki Yokoyama
Hiroyuki Yokoyama
NBNaohito Beppu
Naohito Beppu
MFMasayuki Fujiwara
Masayuki Fujiwara
SHShogo Harui
Shogo Harui
NKNorihiko Kamikonya
Norihiko Kamikonya
This study aimed to assess the clinical outcomes and predictive factors of neoadjuvant modified short-course radiotherapy (mSC-RT) for locally advanced rectal cancer (LARC). Data from 97 patients undergoing mSC-RT followed by radical surgery for LARC were retrospectively analyzed. A 2.5 Gy dose twice daily up to a total dose of 25 Gy in 10 fractions was administered through mSC-RT, and this was delivered with oral chemotherapy in 95 (97.9%) patients. Radical surgery was performed 6 (range, 3–13) weeks after mSC-RT. The median follow-up among surviving patients was 43 (8–86) months. All patients completed neoadjuvant radiotherapy with no acute toxicity grade ≥ 3. Three- and five-year local control rates were 96.3% and 96.3%, respectively. Three- and five-year overall survival (OS) rates were 92.7% and 79.8%, respectively. Univariate analyses revealed that poor OS was associated with no concurrent administration of capecitabine, C-reactive-protein-to-albumin ratio ≥ 0.053, carcinoembryonic antigen ≥ 3.4 ng/mL, and neutrophil-to-lymphocyte ratio (NLR) ≥ 1.83 (P = 0.045, 0.001, 0.041, and 0.001, respectively). Multivariate analyses indicated that NLR ≥ 1.83 was independently associated with poor OS (p = 0.018). mSC-RT followed by delayed surgery for LARC was deemed feasible and resulted in good clinical outcomes, whereas poor OS was associated with high NLR.

20 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
TATsukasa Aihara
Tsukasa Aihara
SIShinichi Ikuta
Shinichi Ikuta
TNTakayoshi Nakajima
Takayoshi Nakajima
SNShinta Nagano
Shinta Nagano
TIToshimitsu Iwasaki
Toshimitsu Iwasaki
NYNaoki Yamanaka
Naoki Yamanaka
Introduction: Radical hepatectomy is the standard curative treatment for colorectal liver metastases (CRLMs). However, extensive resection may be contraindicated in patients with insufficient liver reserve or anatomically complex disease. Although ablation therapy is generally not recommended as a primary curative modality in current guidelines, intraoperative ablation may facilitate parenchymal-sparing, curative-intent treatment in selected high-risk patients. Methods: This retrospective cohort study included 118 patients who underwent curative-intent hepatectomy for multiple CRLM. Patients were categorized into hepatectomy-only (Hx) and hepatectomy plus intraoperative ablation (Hx + Abl) groups, and propensity score matching (PSM) generated 29 balanced pairs. Overall survival (OS) and hepatic progression-free survival (HPFS) were compared using a log-rank test. Cox regression identified predictors of OS, and receiver operating characteristic (ROC) analysis evaluated tumor size associated with local recurrence after ablation. Results: Before PSM, the HX + Abl group showed higher tumor burden and Beppu scores, and demonstrated inferior OS and HPFS. After PSM, oncological outcomes were comparable. Perioperative outcomes, including major complications and post-hepatectomy liver failure (PHLF), were similar. Preoperative chemotherapy was an independent predictor of OS. Among 99 ablated tumors, local recurrence occurred in 12 lesions, and ROC analysis identified tumor size ≤ 15mm as the optimal cutoff predicting local recurrence. Conclusions: In selected high-risk CRLM patients, hepatectomy with intraoperative ablation had no statistically significant difference in OS and HPFS compared with hepatectomy alone without increasing major complications or PHLF.